Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study

Eleonora Lai,Marco Puzzoni,Pina Ziranu,Chiara Cremolini,Sara Lonardi,Maria Banzi,Stefano Mariani,Nicole Liscia,Saverio Cinieri, Manuela Dettori,Manlio Mencoboni,Floriana Nappo,Giulia Piacentini,Roberto Labianca,Gemma Zucchelli,Alessandra Boccaccino,Veronica Conca,Valeria Pusceddu,Alberto Zaniboni,Mario Scartozzi

Clinical Colorectal Cancer（2021）

引用 0|浏览13

暂无评分

摘要

•Regorafenib-treated metastatic colorectal cancer patients with overall survival (OS) ≥ 6 months.•Absence of liver progression and dose/schedule changes: longer OS and progression free survival.•Median OS: 10.8 months longer in absence of liver progression and treatment changes.•Median progression free survival: 7.4 months longer in the same favorable group.•Treatment tolerability and toxicity management were confirmed as crucial factors.

查看译文

关键词

Metastatic colorectal cancer,Long term survivors,Liver progression,Treatment modification,Tolerability

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要